bioRxivCancer BiologyPreprint
DNA-Demethylating Agents enhance cytolytic activity of CD8+ T Cells and anti-tumor immunity
Helen Loo Yau, Ankur Chakravarthy, Felipe Campos de Almeida, David AllardiD, Rajat Singhania, Ilias Ettayebi, Shu Yi Shen, Tiago Medina, Parinaz Mehdipour, Beatriz Morancho, Sandra Pommey, Christian Klein, Gustavo Amarante-Mendes, David Roulois, Marcus Butler, Joaquín Arribas, John StaggiD, Daniel D. De Carvalho
Abstract
Recent studies have shown that DNA methyltransferase inhibitors (DNMTi) can induce IRF7 activation and Type I/III interferon signaling through dsRNA-mediated viral mimicry in cancer cells. By performing a large pan-cancer analysis using TCGA data, we determined that IRF7 activation is associated with higher CD8+ T cell tumor infiltration and higher cytolytic activity across multiple cancer types. Accordingly, we demonstrate that DNMTi treatment results in increased CD8+ T cell tumor infiltration, enhanced cytolytic activity and CD8+ T cell dependent tumor growth inhibition. Finally, we show that DNMTi triggers a process marked by the induction of viral mimicry directly on CD8+ T cells, leading to activation of dsRNA sensing pathway, and up-regulation of T cell activation markers, effector cytokines, and Granzyme B. Taken together, our findings suggest that dsRNA sensing pathway activation in the immune compartment, through pharmacological DNA demethylation, is a viable strategy for boosting anti-tumor immune response.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: gene regulatory network inference
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting DNMT1 augments anti-tumor CD8⁺ T cell function
Maya G. Deshmukh, Danielle K. Sohai, … Goran Micevic·bioRxiv·Jul 6, 2026
- Epigenetic therapy remodels the immune synaptic cytoskeleton to potentiate cancer susceptibility to γδ T cells
R. R. Weng, H.-H. Lu, … H.-C. Tsai·bioRxiv·Apr 30, 2020
- Successful dendritic cell vaccines require lasting in-situ TNF α secretion to license antitumor CD8 + T cell cytotoxicity
Nadine Santana-Magal, Aseel Khateeb, … Yaron Carmi·bioRxiv·Apr 8, 2026
- ATPIF1 inactivation promotes antitumor immunity through metabolic reprogramming of CD8+ T cells
- An NF-κB/IRF1 axis programs cDC1s to drive anti-tumor immunity
G. Ghislat, A. S. Cheema, … T. Lawrence·bioRxiv·Dec 28, 2020
- The Injury Response to DNA Damage Promotes Anti-Tumor Immunity
G. Sriram, L. E. Milling, … M. B. Yaffe·bioRxiv·Apr 26, 2020